[关键词]
[摘要]
特发性肺纤维化(IPF)是一种不可逆、进展性、致死性的慢性肺纤维化疾病,其进展较快,存活率较低,缺乏有效诊疗手段和治疗药物.近年来随着对其发病机制的了解,IPF 治疗药物的开发也取得了一定进展.全球新批准并上市的治疗药物有吡非尼酮和尼达尼布,处于研发I、II 期的有10 多种,另外也有一些曾经有希望但已经不推荐用于IPF 治疗的药物.
[Key word]
[Abstract]
Idiopathic pulmonary fibrosis (IPF) is a chronic pulmonary fibrosis disease with irreversible, progressive, and fatal phenomenon, characterized by rapid progression and high mortality. And there are lack of effective diagnostic methods and treatment drugs. Recently, with the understanding of its pathogenesis, IPF drug development have also made some progress. Pirfenidone and nintedanib are new drugs approved and listed, and there are more than ten IPF drugs under development. In addition, there are some hope for IPF treatment drugs, but now are not recommended.
[中图分类号]
[基金项目]